About

Shawn Grubb now has a new role at Quip Labs!

Wilmington, DE: Quip Labs, the forerunner in full-service biosafety and facility hygiene solutions, is building on its industry-leading customer experience with the addition of Sales Manager Shawn Grubb. “With this new hire, we at Quip Labs aim to improve even further on the already best-in-class customer service we provide and increase our ability to provide

Quip Labs is Going to the National AALAS Virtual Meeting!

Heading to the 2020 National AALAS Virtual Meeting? Be on the look out for Quip Laboratories. We’ll be answering your questions, giving away freebies and providing sneak peaks at the latest and greatest from Quip Laboratories. We’ll also be sharing content that can help your lab stay safe while getting back to work. Stay tuned

Quip Labs Builds on Its Industry Leading Presence with Account Manager and Business Development Officer

Quip Labs Builds on Its Industry Leading Presence with Account Manager and Business Development Officer Wilmington, DE: Quip Labs, the forerunner in full-service biosafety and facility hygiene solutions, has built on its industry leading presence with the addition of a Business Development Officer and a new Biosafety Account Manager. With the addition of Business Development

We’ve partnered with C-Bond Systems to better supply the automotive industries!

We’ve  entered into an exclusive, nationwide distribution agreement with C-Bond Systems for use of MB-10 Tablets, an EPA-registered disinfectant (Reg No.70060-19-46269) to help in the fight against COVID-19. COVID-19 is caused by SARS-CoV-2. This product kills similar viruses and therefore, according to the EPA Guidelines On Emerging Pathogens, can be used against SARS-CoV-2 when used

MB-10 and Vimoba Tablets Make EPA List N

We’re proud to announce that as of March 16th 2020, MB-10 and Vimoba Tablets have been added to the EPA’s List N, a list of the products that the EPA has deemed efficacious against SARS-CoV-2. According to the EPA, “This list includes products with emerging viral pathogen claims and those with human coronavirus claims. If